All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 6, 2022
Breaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Sutro to develop immunostimulatory ADCs for Astellas targets in deal worth $1.3BBreaking News: Free access to BioWorld coronavirus articles
  • Cross section of brain

    Postmortem brain study gives clues to long COVID

    SARS-CoV-2 infection caused damage to brain blood vessels via a cascade of immune system reactions that was most likely initiated by antibody-dependent cytotoxicity, researchers from the National Institute of Neurological Disorders and Stroke reported in the July 5, 2022, online issue of Brain.

Therapeutic sections

  • Cancer
  • Cardiovascular disorders
  • CNS disorders
  • Conferences
  • Dermatalogical disorders
  • Diagnostics and biomarkers
  • Ear, eye and mouth disorders
  • Endocrine and metabolic
  • Gastrointestinal disorders
  • Hematological disorders
  • Immune-mediated disorders
  • Infections and AIDS
  • R&D and business news
  • Renal and urological disorders
  • Respiratory disorders
  • Jiangsu Hansoh Pharmaceutical Group, Shanghai Hansoh Biomedical patent CD73 inhibitors

  • New EGFR inhibitors identified at PharmaBlock Sciences

  • miR-34a induction is an approach against liver metastasis

  • HSP60 as biomarker of chemotherapeutic response in colorectal cancer

  • Bioprinted hepatocyte implants show potential long-term viability in vivo

  • Blockade of DNMT1/UHRF1 complex may be an approach for NAFLD

  • New TYK2 inhibitors discovered at Jiangsu Chia Tai Tianqing Pharmaceutical Group

  • Postmortem brain study gives clues to long COVID

  • Shanghai Visonpharma patents agents for treating hepatitis B virus infections

  • Walden Biosciences enters research collaboration with University of Michigan on suPAR genetics

  • Approved ALK inhibitors may provide pain relief

  • Novel Alzheimer's disease model lacking interaction between FKBP51 and HSP90 generated

  • Novel dual RAGE/SERT inhibitor shows promise as treatment of AD with comorbid depression

  • Beijing Tide Pharmaceutical divulges SOS1/GTPase KRAS interaction inhibitors

  • Identification of SCUBE3 as a novel therapeutic target in HCC

  • New Gly12Cys mutant GTPase KRAS inhibitors patented by Abbisko Therapeutics

  • New TYK2 inhibitors synthesized at Shenzhen Chipscreen Biosciences

  • New protein kinase B inhibitors identified at Nanjing Zhengda Tianqing Pharmaceutical

  • RNA-binding protein helps colon cancer cells persist

  • PTPRK predicts poor prognosis in patients with pancreatic cancer

  • SERPINA1 is associated with poor prognosis and liver metastasis in gastric cancer

  • Jiangsu Zhengda Qingjiang Pharmaceutical presents SLC22A12 inhibitors

  • Targeting RNF41 promotes liver regeneration in mice

  • Janssen, Johnson & Johnson present new compounds for the treatment of hepatitis B

Test tubesBioWorld Science: News for the R&D team that’s laser-focused on preclinical research

BioWorld Science delivers discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages every business day. On this site, you’ll find that the lead article is freely available. The rest of the daily headlines link back to the legacy site. If you’re a subscriber, click on any headline and you’ll be taken back to the original site, which is still active. For more about BioWorld Science, click here.

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing